THIRD AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 8th, 2017 • G1 Therapeutics, Inc. • Pharmaceutical preparations • North Carolina
Contract Type FiledMay 8th, 2017 Company Industry JurisdictionTHIS THIRD AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Third Amendment”) is entered into as of May 5, 2017, by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”) and Mark A. Velleca (the “Executive”).
SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 9th, 2017 • G1 Therapeutics, Inc. • Pharmaceutical preparations • North Carolina
Contract Type FiledFebruary 9th, 2017 Company Industry JurisdictionTHIS SECOND AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Second Amendment”) is entered into and effective as of May 10, 2016, by and between G1 Therapeutics, Inc., a Delaware corporation (the “Company”), and Mark A. Velleca (the “Executive”).
FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 5th, 2016 • G1 Therapeutics, Inc. • Pharmaceutical preparations • North Carolina
Contract Type FiledFebruary 5th, 2016 Company Industry JurisdictionTHIS FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is entered into and effective as of February 1, 2015, by and between GI Therapeutics, Inc., a Delaware corporation (the “Company”) and Mark A. Velleca (the “Executive”).